The Cure For Keloids Old and New
By William Wong, ND, PhD Member World Sports Medicine Hall of Fame.
When a patient goes in for elective plastic surgery, it is most often with the thought that they are improving something about their appearance. The physician keeps aesthetics and symmetry in mind as the work is planned and done much as a sculptor takes care to carve his artwork.
In serious injury when a fracture is compounded and sections of broken bone tears through the skin, great care must be taken not only in reducing the fracture but also in making sure no nerve damage has been done by the break or created in the reduction. The ends of bone are carefully placed back where they can mend and the skin closed and sutured to insure that it all heals.
Ofttimes in car accidents facial lacerations occur from flying shards of glass. If the ER doctor is skilled at closing such wounds he will first suture the gallia, the fine connective tissue layer beneath the skin, mating the ends correctly then carefully closing the skin over that.
What happens after the events described above or any other injury or surgical wound where skin and the connective tissue layers beneath are involved hopefully is healing without scaring and without the formations of keloids. What are keloids? They are hard often unsightly mounds of connective tissue bunched up and over grown; they are a form of fibrosis / scar tissue.
Fibrosis is the result of inflammation. Inflammation caused by the injury, by the surgery, by a burn, whatever the cause inflammation is one of two things that drive the growth of fibrosis. (The other cause of fibrosis growth is estrogen but that is not an operational factor in keloid formation. Long term or intense inflammation is the spark that causes the formation of these mounds of scar tissue). If the inflammation can be brought under control the keloid formation might be arrested. Plastic surgeons routinely have administered local injections of cortisone in attempts to slow down the inflammation and stop the formation of keloids. These attempts are mostly failures and if pronounced the keloid itself may have to be surgically excised, which may in turn begin the round of keloid formation all over again.
It has been taught that a keloid older than a year will remain untreatable regardless of what is done short of surgery. This line of thinking does not hold world wide. Physicians in Central Europe and Japan have for decades been treating various types of fibrosis, from post operative scar tissue, to renal fibrosis, to pulmonary fibrosis with blends of orally administered proteolytic enzymes specifically formulated to be absorbed and act systemically. (1,2,3,4,5.6). To date there are over 200 peer reviewed studies verifying both the absorption and therapeutic action of such enzymes. (See www.enzymescience.com in the abstracts archive).
In Germany the use of systemic enzymes is standard in the post operative prevention of scar tissue, where the enzymes also decrease inflammation (without the side reactions or toxicity of the NSAID’s or steroids), and speed the healing of tissue. It was surmised by some surgeons that if the enzymes could prevent the formation of post operative scar tissue and existing fibrosis in other conditions, that they could also lyse away the fibrosis of keloids. Their assumption was correct.
While no formal studies have yet been done on keloids specifically, the lysing action of the enzymes on other types of fibrosis has been studied and noted. Various plastic surgeons have reported the removal of long standing keloids from their patients. One interesting observation on the fibrosis lysing effect of systemic enzymes came from a plastic surgeon from California. This physician, while using a multi-enzyme product to reduce both the inflammation and post operative scar tissue in his patients, was taking the product himself to lower visceral inflammation levels and bring down CRP and Homocystine levels. After several weeks on the product he reported that a 40 year old keloid the size of a small egg that had grown on his left hand, as the result of a compound fracture, had been completely lysed away! Various other plastic surgeons report the removal of long standing keloids from patients.
Up to now there has been no sure treatment for the prevention or elimination of keloids. With the use of Systemic Enzymes, such as those found in Zymessence™, there is now a powerful, effective, yet completely safe and non toxic tool for the treatment of this form of fibrosis. The effect of enzymes is dose dependent and results may be seen seen in weeks or some months depending on the size of and circulation to the keloid.
1) Transport of Proteolytic Enzymes Across Caco-2 Cell Monolayers
Bock U.,1 Kolac C.,1 Borchard G.,1 KochK.,1 Fuchs R.,1 Streichhan P.,2 and Lehr C.-M.1
1 Department of Biopharmaceutics and Pharmaceutical Technology, University of Saarland, Saarbrücken, Germany
2 Mucos Pharma GmbH, Geretsried, Germany
Pharmaceutical Research 1998, Vol. 15, No. 9, pp. 1393-1400.
2) Intestinal absorption of serrapeptase (TSP) in rats.
Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A.
Biotechnol Appl Biochem. 1994 Aug;20 ( Pt 1):101-8.
Biotechnology Research Laboratories, Takeda Chemical Industries Ltd., Osaka, Japan.
3) Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo.
Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, Guarini E, Vesperini G.
J Int Med Res. 1990 Sep-Oct;18(5):379-88.
Institute of Clinical Otorhinolaryngology, University of Naples, Italy.
4) Anti-inflammatory and analgesic activity of ExCLzyme-EN®
S.L.Bodhankar, A.U.Burhan, V.M.Kale, S.Banerjee and S. Risbud
Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Pune 411 038.
Raj Biotech Pvt. Ltd., Pune 411038
Group Companies of Specialty Enzymes and Biochemicals Co., Chino, California 91710 and Advanced Biochemicals Ltd. Thane 400601.
5) Renal fibrosis: Role of impaired protein degradation and potential therapeutic strategies
Heidland A.1, Sebekova K.2, Paczek L.3, Teschner M.1, Daemmrich J.4, Gaciong Z.3
1 Medical Faculty, University of Wuerzburg, 2 Institute of Preventive and Clinical Medicine, Bratislava (Slovakia), 3 The Transplantation Institute Warsaw (Poland), 4 Institute of Pathology, University of Wuerzburg (Germany)
Kidney International 1997, Vol. 52, Suppl. 62, pp. S 32- S 35
6) Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria, and mesangial proliferation in murine experimental IgA nephropathy
Gesualdo L., Ricanati S., Hassan M.O., Emancipator S.N., Lamm M.E.
Institute of Pathology and the *Department of Pathology, Veterans Administration Hospital, Case Western Reserve University, Cleveland, Ohio 44106
J. Clin. Invest. 1990: Vol. 86, September 1990, pp. 715-722